BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 22864527)

  • 1. Oral mucosa produces cytokines and factors influencing osteoclast activity and endothelial cell proliferation, in patients with osteonecrosis of jaw after treatment with zoledronic acid.
    Mozzati M; Martinasso G; Maggiora M; Scoletta M; Zambelli M; Carossa S; Oraldi M; Muzio G; Canuto RA
    Clin Oral Investig; 2013 May; 17(4):1259-66. PubMed ID: 22864527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear factor-kappa B ligand and osteoprotegerin levels in serum and gingival crevicular fluid in patients with bone metastases treated with zoledronic acid.
    Inanc M; Kaynar L; Enhos S; Pala C; Karaca H; Berk V; Ozkan M; Sıvgın S; Eser B; Cetin M; Elmali F
    Med Oncol; 2014 Mar; 31(3):837. PubMed ID: 24448976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonate therapy for skeletal malignancies and metastases: impact on jaw bones and prosthodontic concerns.
    Tripathi A; Pandey S; Singh SV; Kumar Sharma N; Singh R
    J Prosthodont; 2011 Oct; 20(7):601-3. PubMed ID: 21883630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.
    Cetiner S; Sucak GT; Kahraman SA; Aki SZ; Kocakahyaoglu B; Gultekin SE; Cetiner M; Haznedar R
    J Bone Miner Metab; 2009; 27(4):435-43. PubMed ID: 19240969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventive oral surgery before bisphosphonate administration to reduce osteonecrosis of the jaws.
    Mozzati M; Maggiora M; Scoletta M; Vasta A; Canuto R; Muzio G
    Oral Dis; 2014 Nov; 20(8):809-14. PubMed ID: 24330028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
    Gartrell BA; Coleman RE; Fizazi K; Miller K; Saad F; Sternberg CN; Galsky MD
    Eur Urol; 2014 Feb; 65(2):278-86. PubMed ID: 23706567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice.
    Kobayashi Y; Hiraga T; Ueda A; Wang L; Matsumoto-Nakano M; Hata K; Yatani H; Yoneda T
    J Bone Miner Metab; 2010 Mar; 28(2):165-75. PubMed ID: 19882100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of hyperbaric oxygen therapy on tooth extraction sites in rats subjected to bisphosphonate therapy-histomorphometric and immunohistochemical analysis.
    Silva ML; Tasso L; Azambuja AA; Figueiredo MA; Salum FG; da Silva VD; Cherubini K
    Clin Oral Investig; 2017 Jan; 21(1):199-210. PubMed ID: 26955837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoledronic acid - related osteonecrosis of the jaws. Experimental model with dental extractions in rats.
    Barba-Recreo P; Del Castillo Pardo de Vera JL; García-Arranz M; Yébenes L; Burgueño M
    J Craniomaxillofac Surg; 2014 Sep; 42(6):744-50. PubMed ID: 24342733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates.
    DE Iuliis F; Taglieri L; Amoroso L; Vendittozzi S; Blasi L; Salerno G; Lanza R; Scarpa S
    Anticancer Res; 2014 May; 34(5):2477-80. PubMed ID: 24778063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic.
    Nomura T; Shibahara T; Uchiyama T; Yamamoto N; Shibui T; Yakushiji T; Watanabe A; Muramatsu K; Ogane S; Murayama M; Sekine R; Nakata E; Fujimoto Y
    Bull Tokyo Dent Coll; 2013; 54(2):117-25. PubMed ID: 23903583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: a possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw?
    Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Ristow M; Koerdt S; Schuster R; Otto S; Pautke C
    J Cancer Res Clin Oncol; 2014 Mar; 140(3):487-93. PubMed ID: 24469255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teriparatide and the treatment of bisphosphonate-related osteonecrosis of the jaw: a rat model.
    Ersan N; van Ruijven LJ; Bronckers AL; Olgaç V; Ilgüy D; Everts V
    Dentomaxillofac Radiol; 2014; 43(1):20130144. PubMed ID: 24170800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management.
    Ruggiero SL; Fantasia J; Carlson E
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Oct; 102(4):433-41. PubMed ID: 16997108
    [No Abstract]   [Full Text] [Related]  

  • 15. Exposing human epithelial cells to zoledronic acid can mediate osteonecrosis of jaw: an in vitro model.
    Saracino S; Canuto RA; Maggiora M; Oraldi M; Scoletta M; Ciuffreda L; Vandone AM; Carossa S; Mozzati M; Muzio G
    J Oral Pathol Med; 2012 Nov; 41(10):788-92. PubMed ID: 22650360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma.
    Diego R; D'Orto O; Pagani D; Agazzi A; Marzano U; Derada Troletti G; Fontanella W; Pignataro L
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar; 103(3):e1-5. PubMed ID: 17197204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonate-related osteonecrosis of the jaws--a case report.
    Kamoh AK; Ogle O
    Compend Contin Educ Dent; 2012 May; 33(5):e74-7. PubMed ID: 23268588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.
    Wutzl A; Eisenmenger G; Hoffmann M; Czerny C; Moser D; Pietschmann P; Ewers R; Baumann A
    Wien Klin Wochenschr; 2006 Aug; 118(15-16):473-8. PubMed ID: 16957978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonate-induced osteonecrosis of the jaw in patients with bone metastatic, hormone-sensitive prostate cancer. Risk factors and prevention strategies.
    Bantis A; Zissimopoulos A; Sountoulides P; Kalaitzis C; Giannakopoulos S; Deftereos S; Tsakaldimis G; Thomaidis V; Touloupidis S
    Tumori; 2011; 97(4):479-83. PubMed ID: 21989437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonate-related osteonecrosis: laser-assisted surgical treatment or conventional surgery?
    Atalay B; Yalcin S; Emes Y; Aktas I; Aybar B; Issever H; Mandel NM; Cetin O; Oncu B
    Lasers Med Sci; 2011 Nov; 26(6):815-23. PubMed ID: 21809068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.